← All companies

ODTX

Odyssey Therapeutics, Inc.

ODTX Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$18.13

-0.29 -1.57%

Key statistics

from XBRL data in SEC filings

Market cap

$871M

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

$35.7M

Total assets

$229M

Gross margin

—

52-week range

$15.10 – $20.30

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Results of operations (earnings release) Aug 4, 2026 8-K Regulation FD disclosure Jun 23, 2026 10-Q Quarter ended 2026-03-31 Jun 17, 2026 8-K Results of operations (earnings release) Jun 17, 2026 8-K Entered a material agreement; Unregistered sale of equity; Amended charter or bylaws May 11, 2026

Other filings

SCHEDULE 13G Jun 5, 2026 SCHEDULE 13G May 18, 2026 SCHEDULE 13D May 18, 2026 SCHEDULE 13D May 18, 2026 SCHEDULE 13D May 15, 2026 SCHEDULE 13D May 15, 2026 4 FORM 4 May 13, 2026 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES May 12, 2026 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES May 12, 2026 4 May 11, 2026 4 May 11, 2026 4 May 11, 2026 4 May 11, 2026 4 May 11, 2026 4 May 11, 2026 4 May 11, 2026 4 May 11, 2026 4 May 11, 2026 4 May 11, 2026 4 May 11, 2026 4 May 11, 2026 4 May 11, 2026 S-8 May 11, 2026 424B4 May 8, 2026 EFFECT May 7, 2026 3 May 7, 2026 3 May 7, 2026 3 May 7, 2026 3 May 7, 2026 3 May 7, 2026 3 May 7, 2026 3 May 7, 2026 3 May 7, 2026 3 May 7, 2026 3 May 7, 2026